We will work to make our medicines available by considering both effective affordability strategies and innovative solutions to disease management, as well as off-patent solutions to complement our innovative medicines portfolio.
We will price our new medicines based on the value they deliver to patients, healthcare systems and society
To help improve the affordability of our medicines, we will strive to take into account income levels, local affordability barriers and economic realities, while maintaining the sustainability of our business
We plan to conduct regular reviews of prices and affordability strategies as part of our global access strategy reviews to ensure alignment with our access principles
Our patient assistance programs and social business models are to be appropriately scaled to expand their reach and impact